Coherus BioSciences

$18.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (+1.65%) Today

$0.00 (0.00%) As of 7:08 AM EST after-hours

Why Robinhood?

You can buy or sell CHRS and other stocks, options, and ETFs commission-free!

About CHRS

Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA. The listed name for CHRS is Coherus BioSciences, Inc. Common Stock.

CEO

Denny M. Lanfear

Employees

291

Headquarters

Redwood City, California

Founded

2010

Market Cap

1.33B

Price-Earnings Ratio

9.26

Dividend Yield

—

Average Volume

787.44K

High Today

$18.57

Low Today

$18.15

Open Price

$18.48

Volume

632.94K

52 Week High

$23.03

52 Week Low

$10.86

Collections

Analyst Ratings

90%

of 10 ratings

Buy

90%

Hold

10%

Sell

CHRS Earnings

-$0.46

-$0.04

$0.39

$0.81

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, After Hours